ClinicalTrials.gg
TerminatedNCT04685850SEINEUpdated Jun 13, 2025

Long-term Sequelae of Childhood Meningitis and Meningococcal Purpura Fulminans

An observational study in Meningitis, Meningococcal and Sequela, sponsored by Centre Hospitalier Intercommunal Creteil. Terminated at 9 sites in France. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Centre Hospitalier Intercommunal Creteil · Observational

How we know

Why this study was terminated
lack of inclusion

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
43
Ages
Up to 17 Years
Sex
All
01

Study summary

While the initial evolution of meningococcal meningitis (MM) is well described, there are few data on the long-term evolution, beyond 1 year.

The objective of this research is to evaluate the sequelae of MM beyond 1 year in patients with a history of MM followed in Paris area, France. Most children with MM in France have been included in the MM register and are still being followed. Parents will be offered a detailed clinical evaluation of their child including: a clinical and neurological examination, a cognitive performance assessment, an auditory, speech and visual assessment and an evaluation of the child's progress at school.

02

Conditions studied

  • Meningitis, Meningococcal
  • Sequela
03

In context

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

This study's enrollment of 43 is below the median of 180 across 11 observational studies indexed under Meningitis, Meningococcal.

Browse Meningitis, Meningococcal studies →

Lead sponsor

Centre Hospitalier Intercommunal Creteil is the lead sponsor of 132 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children from 0 to 17 years old who had meningococcal meningitis between 2010 and 2019

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants and children from 0 to 17 years old
  • Having had meningitis or meningococcal purpura fulminans between 2010 and 2021
  • Delay ≥ 1 year between the date of diagnosis of meningitis or purpura meningococcal fulminans and the date of inclusion in the study (signature of the )
  • The holders of parental authority have read and understood the information letter and their express consent has been obtained
  • Patient affiliated to a social security system (Social Security or Universal Medical Coverage)

Exclusion criteria

Exclusion Criteria:

  • refusal to participate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
43 participants (actual)
Patient registry
No

Interventions

  • Othersequela evaluation

    clinical and neurological examination, psychological evaluation (cognitive performance), an auditory, speech and visual assessment and an evaluation of the child's school performance

06

What researchers measure

Primary outcomes

  1. Number of children with at least one neurological, orthopedic or sensory sequelae

    Time frame: 1 year

Secondary outcomes

  1. Number of children with severe neurological sequelae

    Time frame: 1 year

  2. Number of children with orthopedic complications

    Time frame: 1 year

  3. Number of children with sensory disorders

    Time frame: 1 year

  4. Number of children with skin sequelae

    Time frame: 1 year

  5. Number of children with learning disabilities

    Time frame: 1 year

  6. Number of children with cognitive or psychological difficulties identified on the WPPSI, WISC V or VINELAND depending on their age and capacity

    95% of the population has a Total IQ between 70 and 130 (from low intelligence to high intelligence).

    Time frame: 1 year

  7. Number of consultations during follow-up

    Time frame: 1 year

  8. Post-traumatic stress in parents using the IES-R questionnaire

    A score up to 33 is associated with a stress post traumatic

    Time frame: 1 year

07

Study locations

9 sites
  • CHU Bicêtre
    Le Kremlin Bicêtre, Kremlin Bicêtre 94720, France
  • CHU Annecy
    Annecy, 74370, France
  • Centre Intercommunal de Villeneuve Saint Georges
    Crosne, 91560, France
  • CHI créteil
    Créteil, 94000, France
  • Groupe Hospitalier Nord Essonne
    Longjumeau, 91345, France
  • GHEF site de Meaux
    Meaux, 77100, France
  • Hôpital Necker Enfants Malades
    Paris, 75015, France
  • Robert debré hospital
    Paris, 75019, France
  • Ch Pontoise
    Pontoise, 95300, France
08

References and documents

Publications

  • Baloche A, Jung C, Levy M, Elbez-Rubinstein A, Bechet S, Layouni I, Monguillot G, Taha MK, Cohen R, Levy C. Long-term impact of invasive meningococcal disease in children: SEINE study protocol. PLoS One. 2022 May 26;17(5):e0268536. doi: 10.1371/journal.pone.0268536. eCollection 2022. PubMed 35617288 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in May 2025, 46 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2020
First posted
Dec 28, 2020
StartActual
Jul 9, 2021
Primary completionActual
May 19, 2025
CompletionActual
May 19, 2025
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04685850
Collaborators
Association Clinique Thérapeutique Infantile du val de Marne
Responsible party
Sponsor
First posted
Dec 28, 2020
Start date
Jul 9, 2021
Primary completion
May 19, 2025
Completion
May 19, 2025
Last update
Jun 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion